Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicine
ABSTRACT Plasmalogens are natural glycerophospholipids that account for approximately 15%–20% (mol%) of human tissues' cellular membrane phospholipid composition. They play an important role in lipid membrane organization and function, including acting as endogenous antioxidants. Plasmalogens c...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | FASEB BioAdvances |
| Subjects: | |
| Online Access: | https://doi.org/10.1096/fba.2025-00010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221938524717056 |
|---|---|
| author | Yu Wu Yuru Deng Borislav Angelov Angelina Angelova |
| author_facet | Yu Wu Yuru Deng Borislav Angelov Angelina Angelova |
| author_sort | Yu Wu |
| collection | DOAJ |
| description | ABSTRACT Plasmalogens are natural glycerophospholipids that account for approximately 15%–20% (mol%) of human tissues' cellular membrane phospholipid composition. They play an important role in lipid membrane organization and function, including acting as endogenous antioxidants. Plasmalogens contain a vinyl‐ether linked alkyl chain at position sn‐1, characteristic of vinyl‐ether lipids, and often a polyunsaturated fatty acid (PUFA) acyl chain at position sn‐2 of the glycerol backbone. The role of plasmalogens in various patho‐physiological processes has been revealed in recent years, including various neurological disorders associated with plasmalogen deficiency. Plasmalogen Replacement Therapy (PRT) is a therapeutic approach that aims to increase plasmalogen levels in the body and address plasmalogen deficiencies in diseases such as age‐related neurodegenerative diseases, cardiovascular diseases, certain genetic peroxisomal disorders, and metabolic disorders. We provide a detailed overview of current information on the role of plasmalogens in health and disease. We summarize various strategies for regulating plasmalogen levels and highlight recent advancements in therapeutic applications. We also focus on the potential application of nanomedicine for treating disorders associated with PUFA‐lipid and plasmalogen deficiencies. |
| format | Article |
| id | doaj-art-43a3577c356b4c1787cab5e252777e76 |
| institution | Kabale University |
| issn | 2573-9832 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | FASEB BioAdvances |
| spelling | doaj-art-43a3577c356b4c1787cab5e252777e762025-08-26T10:37:10ZengWileyFASEB BioAdvances2573-98322025-08-0178n/an/a10.1096/fba.2025-00010Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in NanomedicineYu Wu0Yuru Deng1Borislav Angelov2Angelina Angelova3Université Paris‐Saclay, CNRS, Institut Galien Paris‐Saclay Orsay FranceWenzhou Institute, University of Chinese Academy of Sciences Wenzhou Zhejiang ChinaDepartment of Structural Dynamics Extreme Light Infrastructure ERIC Dolni Brezany Czech RepublicUniversité Paris‐Saclay, CNRS, Institut Galien Paris‐Saclay Orsay FranceABSTRACT Plasmalogens are natural glycerophospholipids that account for approximately 15%–20% (mol%) of human tissues' cellular membrane phospholipid composition. They play an important role in lipid membrane organization and function, including acting as endogenous antioxidants. Plasmalogens contain a vinyl‐ether linked alkyl chain at position sn‐1, characteristic of vinyl‐ether lipids, and often a polyunsaturated fatty acid (PUFA) acyl chain at position sn‐2 of the glycerol backbone. The role of plasmalogens in various patho‐physiological processes has been revealed in recent years, including various neurological disorders associated with plasmalogen deficiency. Plasmalogen Replacement Therapy (PRT) is a therapeutic approach that aims to increase plasmalogen levels in the body and address plasmalogen deficiencies in diseases such as age‐related neurodegenerative diseases, cardiovascular diseases, certain genetic peroxisomal disorders, and metabolic disorders. We provide a detailed overview of current information on the role of plasmalogens in health and disease. We summarize various strategies for regulating plasmalogen levels and highlight recent advancements in therapeutic applications. We also focus on the potential application of nanomedicine for treating disorders associated with PUFA‐lipid and plasmalogen deficiencies.https://doi.org/10.1096/fba.2025-00010bioactive lipidsdrug deliverylipid replacement therapynanomedicineneuroregenerationPUFA‐plasmalogens |
| spellingShingle | Yu Wu Yuru Deng Borislav Angelov Angelina Angelova Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicine FASEB BioAdvances bioactive lipids drug delivery lipid replacement therapy nanomedicine neuroregeneration PUFA‐plasmalogens |
| title | Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicine |
| title_full | Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicine |
| title_fullStr | Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicine |
| title_full_unstemmed | Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicine |
| title_short | Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicine |
| title_sort | plasmalogen as a bioactive lipid drug from preclinical research challenges to opportunities in nanomedicine |
| topic | bioactive lipids drug delivery lipid replacement therapy nanomedicine neuroregeneration PUFA‐plasmalogens |
| url | https://doi.org/10.1096/fba.2025-00010 |
| work_keys_str_mv | AT yuwu plasmalogenasabioactivelipiddrugfrompreclinicalresearchchallengestoopportunitiesinnanomedicine AT yurudeng plasmalogenasabioactivelipiddrugfrompreclinicalresearchchallengestoopportunitiesinnanomedicine AT borislavangelov plasmalogenasabioactivelipiddrugfrompreclinicalresearchchallengestoopportunitiesinnanomedicine AT angelinaangelova plasmalogenasabioactivelipiddrugfrompreclinicalresearchchallengestoopportunitiesinnanomedicine |